| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
189,490,000 |
| Market
Cap: |
1.14(B) |
| Last
Volume: |
2,547,018 |
Avg
Vol: |
4,440,946 |
| 52
Week Range: |
$4.13 - $7.98 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 16.9 |
| Insider 6 Months : 16.9 |
| Insider 3/6 Months : 32.4 |
|
| Guru Rank Number : 455 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
183,601 |
183,601 |
183,601 |
183,601 |
| Total Buy Value |
$1,048,338 |
$1,048,338 |
$1,048,338 |
$1,048,338 |
| Total People Bought |
10 |
10 |
10 |
10 |
| Total Buy Transactions |
10 |
10 |
10 |
10 |
| Total Shares Sold |
11,387 |
11,387 |
11,387 |
506,586 |
| Total Sell Value |
$69,059 |
$69,059 |
$69,059 |
$6,068,300 |
| Total People Sold |
2 |
2 |
2 |
10 |
| Total Sell Transactions |
2 |
2 |
2 |
16 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Baker Felix |
10% Owner |
– – • |
2009-05-28 |
4 |
S |
$4.45 |
$486,610 |
I/I |
(108,472) |
1,650,021 |
|
- |
|
| Baker Felix |
10% Owner |
– – • |
2009-05-28 |
4 |
S |
$4.45 |
$32,631 |
I/I |
(7,274) |
129,414 |
|
- |
|
| Baker Felix |
10% Owner |
– – • |
2009-05-28 |
4 |
S |
$4.45 |
$77,618 |
I/I |
(17,302) |
92,414 |
|
- |
|
| Baker Felix |
10% Owner |
– – • |
2009-05-28 |
4 |
S |
$4.45 |
$20,752 |
I/I |
(4,626) |
22,700 |
|
- |
|
| Erck Stanley C |
Director |
– • – |
2009-03-12 |
4 |
B |
$1.22 |
$48,880 |
D/D |
40,000 |
40,000 |
2.39 |
- |
|
| Sheridan William P |
SR VP - CMO |
• – – |
2009-01-30 |
4 |
B |
$1.62 |
$4,845 |
D/D |
3,000 |
3,000 |
2.66 |
- |
|
| Grant Stuart |
SR VP & CFO |
• – – |
2009-01-30 |
4 |
B |
$1.62 |
$4,845 |
D/D |
3,000 |
6,000 |
2.66 |
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2009-01-30 |
4 |
B |
$1.62 |
$4,845 |
D/D |
3,000 |
103,603 |
2.73 |
- |
|
| Mills Mike |
Principal Accounting OfficerOf |
• – – |
2009-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
798 |
|
- |
|
| Babu Yarlagadda S |
VP Drug DiscoveryOfficer |
• – – |
2008-12-23 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
69,362 |
|
- |
|
| Babu Yarlagadda S |
VP Drug DiscoveryOfficer |
• – – |
2008-12-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
57,650 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2008-12-01 |
4 |
B |
$1.48 |
$81,450 |
D/D |
55,000 |
155,603 |
2.81 |
- |
|
| Baker Felix |
10% Owner |
– – • |
2008-11-24 |
4 |
B |
$0.98 |
$7,237 |
I/I |
7,401 |
4,348,466 |
1.5 |
- |
|
| Baker Felix |
10% Owner |
– – • |
2008-11-24 |
4 |
B |
$0.98 |
$10 |
I/I |
10 |
109,716 |
1.42 |
- |
|
| Baker Felix |
10% Owner |
– – • |
2008-11-24 |
4 |
B |
$0.98 |
$2,287 |
I/I |
2,339 |
1,758,493 |
1.42 |
- |
|
| Baker Felix |
10% Owner |
– – • |
2008-11-24 |
4 |
B |
$0.98 |
$197 |
I/I |
201 |
136,688 |
1.42 |
- |
|
| Baker Felix |
10% Owner |
– – • |
2008-11-24 |
4 |
B |
$0.98 |
$48 |
I/I |
49 |
27,326 |
1.42 |
- |
|
| Baker Felix |
10% Owner |
– – • |
2008-11-21 |
4 |
B |
$0.91 |
$28,402 |
I/I |
31,071 |
4,341,065 |
1.5 |
- |
|
| Baker Felix |
10% Owner |
– – • |
2008-11-21 |
4 |
B |
$0.91 |
$39 |
I/I |
43 |
109,706 |
1.42 |
- |
|
| Baker Felix |
10% Owner |
– – • |
2008-11-21 |
4 |
B |
$0.91 |
$8,987 |
I/I |
9,831 |
1,756,154 |
1.5 |
- |
|
| Baker Felix |
10% Owner |
– – • |
2008-11-21 |
4 |
B |
$0.91 |
$775 |
I/I |
848 |
136,487 |
1.42 |
- |
|
| Baker Felix |
10% Owner |
– – • |
2008-11-21 |
4 |
B |
$0.91 |
$189 |
I/I |
207 |
27,277 |
1.42 |
- |
|
| Baker Felix |
10% Owner |
– – • |
2008-11-20 |
4 |
B |
$1.00 |
$303,517 |
I/I |
303,517 |
4,309,994 |
1.5 |
- |
|
| Baker Felix |
10% Owner |
– – • |
2008-11-20 |
4 |
B |
$1.00 |
$422 |
I/I |
422 |
109,663 |
1.42 |
- |
|
| Baker Felix |
10% Owner |
– – • |
2008-11-20 |
4 |
B |
$1.00 |
$96,033 |
I/I |
96,033 |
1,746,323 |
1.5 |
- |
|
754 Records found
|
|
Page 27 of 31 |
|
|
0.24 (3.85%) 
